Cargando…
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study
INTRODUCTION: Dual antiplatelet therapy, aspirin and a P2Y(12) inhibitor, is recommended to prevent thrombotic complications of acute coronary syndrome. Clopidogrel plus acetylsalicylic acid combination is the most commonly used dual antiplatelet therapy recommended by international guidelines and i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467447/ https://www.ncbi.nlm.nih.gov/pubmed/32418143 http://dx.doi.org/10.1007/s12325-020-01369-z |
_version_ | 1783578015143297024 |
---|---|
author | Wang, Lu Di, Yujing Guo, Tingting Ming, Jeffrey E. Kong, Fangyuan Yin, Huiqiu Zhang, Linlin Xie, Fang Yang, Na Ping, Chuan Li, Yi Hou, Jie |
author_facet | Wang, Lu Di, Yujing Guo, Tingting Ming, Jeffrey E. Kong, Fangyuan Yin, Huiqiu Zhang, Linlin Xie, Fang Yang, Na Ping, Chuan Li, Yi Hou, Jie |
author_sort | Wang, Lu |
collection | PubMed |
description | INTRODUCTION: Dual antiplatelet therapy, aspirin and a P2Y(12) inhibitor, is recommended to prevent thrombotic complications of acute coronary syndrome. Clopidogrel plus acetylsalicylic acid combination is the most commonly used dual antiplatelet therapy recommended by international guidelines and in Chinese clinical practice. Poor adherence to dual antiplatelet therapy or premature interruption of dual antiplatelet therapy is an important contributor to cardiovascular mortality and lethal cardiovascular events. Clopidogrel + acetylsalicylic acid fixed-dose combination enhances adherence to dual antiplatelet therapy. Herein, we aimed to evaluate bioequivalence of acetylsalicylic acid and clopidogrel in fixed-dose combination compared with simultaneous administration of their individual formulations in healthy Chinese subjects under fasting conditions. METHODS: This was a randomized, single-center, open-label, three-sequence, three-period, two-treatment, crossover study with a washout period of 10 days conducted in healthy Chinese volunteers. Subjects were randomized to receive Co-Plavix(®) (test formulation- fixed-dose combination of 100 mg acetylsalicylic acid and 75 mg clopidogrel) once and reference formulations (coadministration of individual formulations of 100 mg acetylsalicylic acid and 75 mg clopidogrel) twice during the study period. Pharmacokinetic parameters were analyzed for acetylsalicylic acid, its metabolite salicylic acid, clopidogrel, and its metabolite SR26334. As acetylsalicylic acid shows high intrasubject variability, the reference-scaled average bioequivalence (RSABE) approach was implemented for acetylsalicylic acid analysis, while bioequivalence of clopidogrel was assessed using the average bioequivalence method. Point ratios and confidence intervals (CIs) for AUC, AUC(last), and C(max) for acetylsalicylic acid and clopidogrel were calculated. RESULTS: In total, 171 healthy subjects were enrolled in this study. Subjects were randomized and 170 subjects were treated with test or reference formulation; 164 subjects completed the study. Regarding acetylsalicylic acid exposure, as reference within-subject standard deviation (SD(W)) was at least 0.294 for acetylsalicylic acid C(max), AUC(last), and AUC, the RSABE analysis method was used to assess bioequivalence for all three parameters. The point estimates were within the 0.80–1.25 range (1.19, 1.09, and 1.04, respectively), and upper one-sided 95% CIs of scaled average bioequivalence metric were at most 0 (− 0.30, − 0.14, and − 0.10, respectively). Thus, bioequivalence was demonstrated with acetylsalicylic acid. Bioequivalence was also achieved with clopidogrel as the 90% CIs for geometric mean ratios of clopidogrel C(max), AUC(last), and AUC were within the bioequivalence range (0.80–1.25). CONCLUSION: Application of the reference-scaled average bioequivalence approach to evaluate bioequivalence of acetylsalicylic acid in Chinese male and female healthy volunteers under fasting conditions demonstrated bioequivalence of test and reference formulations. TRIAL REGISTRATION: CTR20181695. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01369-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7467447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-74674472020-09-11 Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study Wang, Lu Di, Yujing Guo, Tingting Ming, Jeffrey E. Kong, Fangyuan Yin, Huiqiu Zhang, Linlin Xie, Fang Yang, Na Ping, Chuan Li, Yi Hou, Jie Adv Ther Original Research INTRODUCTION: Dual antiplatelet therapy, aspirin and a P2Y(12) inhibitor, is recommended to prevent thrombotic complications of acute coronary syndrome. Clopidogrel plus acetylsalicylic acid combination is the most commonly used dual antiplatelet therapy recommended by international guidelines and in Chinese clinical practice. Poor adherence to dual antiplatelet therapy or premature interruption of dual antiplatelet therapy is an important contributor to cardiovascular mortality and lethal cardiovascular events. Clopidogrel + acetylsalicylic acid fixed-dose combination enhances adherence to dual antiplatelet therapy. Herein, we aimed to evaluate bioequivalence of acetylsalicylic acid and clopidogrel in fixed-dose combination compared with simultaneous administration of their individual formulations in healthy Chinese subjects under fasting conditions. METHODS: This was a randomized, single-center, open-label, three-sequence, three-period, two-treatment, crossover study with a washout period of 10 days conducted in healthy Chinese volunteers. Subjects were randomized to receive Co-Plavix(®) (test formulation- fixed-dose combination of 100 mg acetylsalicylic acid and 75 mg clopidogrel) once and reference formulations (coadministration of individual formulations of 100 mg acetylsalicylic acid and 75 mg clopidogrel) twice during the study period. Pharmacokinetic parameters were analyzed for acetylsalicylic acid, its metabolite salicylic acid, clopidogrel, and its metabolite SR26334. As acetylsalicylic acid shows high intrasubject variability, the reference-scaled average bioequivalence (RSABE) approach was implemented for acetylsalicylic acid analysis, while bioequivalence of clopidogrel was assessed using the average bioequivalence method. Point ratios and confidence intervals (CIs) for AUC, AUC(last), and C(max) for acetylsalicylic acid and clopidogrel were calculated. RESULTS: In total, 171 healthy subjects were enrolled in this study. Subjects were randomized and 170 subjects were treated with test or reference formulation; 164 subjects completed the study. Regarding acetylsalicylic acid exposure, as reference within-subject standard deviation (SD(W)) was at least 0.294 for acetylsalicylic acid C(max), AUC(last), and AUC, the RSABE analysis method was used to assess bioequivalence for all three parameters. The point estimates were within the 0.80–1.25 range (1.19, 1.09, and 1.04, respectively), and upper one-sided 95% CIs of scaled average bioequivalence metric were at most 0 (− 0.30, − 0.14, and − 0.10, respectively). Thus, bioequivalence was demonstrated with acetylsalicylic acid. Bioequivalence was also achieved with clopidogrel as the 90% CIs for geometric mean ratios of clopidogrel C(max), AUC(last), and AUC were within the bioequivalence range (0.80–1.25). CONCLUSION: Application of the reference-scaled average bioequivalence approach to evaluate bioequivalence of acetylsalicylic acid in Chinese male and female healthy volunteers under fasting conditions demonstrated bioequivalence of test and reference formulations. TRIAL REGISTRATION: CTR20181695. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-020-01369-z) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-05-16 2020 /pmc/articles/PMC7467447/ /pubmed/32418143 http://dx.doi.org/10.1007/s12325-020-01369-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Wang, Lu Di, Yujing Guo, Tingting Ming, Jeffrey E. Kong, Fangyuan Yin, Huiqiu Zhang, Linlin Xie, Fang Yang, Na Ping, Chuan Li, Yi Hou, Jie Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title | Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title_full | Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title_fullStr | Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title_full_unstemmed | Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title_short | Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study |
title_sort | implementation of a reference-scaled average bioequivalence approach for highly variable acetylsalicylic acid in fixed-dose combination with clopidogrel versus enteric aspirin in chinese subjects under fasting conditions: a phase 1, open-label, randomized, crossover study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467447/ https://www.ncbi.nlm.nih.gov/pubmed/32418143 http://dx.doi.org/10.1007/s12325-020-01369-z |
work_keys_str_mv | AT wanglu implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT diyujing implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT guotingting implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT mingjeffreye implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT kongfangyuan implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT yinhuiqiu implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT zhanglinlin implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT xiefang implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT yangna implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT pingchuan implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT liyi implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy AT houjie implementationofareferencescaledaveragebioequivalenceapproachforhighlyvariableacetylsalicylicacidinfixeddosecombinationwithclopidogrelversusentericaspirininchinesesubjectsunderfastingconditionsaphase1openlabelrandomizedcrossoverstudy |